Camptothecin Induces Apoptosis of Human Retinoblastoma Cells via Activation of FOXO1

REFERENCES

• Mahoney MC, Burnett WS, Majerovics A, et al. The epidemiology of ophthalmic malignancies in New York State. Ophthalmology. 1990;97:1143–1147.
   PubMed Web of Science ®Google Scholar
• Suárez F, Jockovich ME, Hernandez E, et al. Paclitaxel in the treatment of retinal tumors of LH beta-Tag murine transgenic model of retinoblastoma. Invest Ophthalmol Vis Sci. 2007;48:3437–3440.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol. 2003;21:2019–2025.
   PubMed Web of Science ®Google Scholar
• Gallie BL, Budning A, DeBoer G, et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol. 1996;114:1321–1328.
   PubMed Web of Science ®Google Scholar
• Murphree AL, Villablanca JG, Deegan WF, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol. 1996;114:1348–1356.
   PubMed Web of Science ®Google Scholar
• Wilson TW, Chan HS, Moselhy GM, et al. Penetration of chemotherapy into vitreous is increased by cryotherapy and cyclosporine in rabbits. Arch Ophthalmol. 1996;114:1390–1395.
   PubMed Web of Science ®Google Scholar
• Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction plus focal therapy for retinoblastoma: Factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol. 2002;133:657–664.
   PubMed Web of Science ®Google Scholar
• Laurie NA, Gray JK, Zhang J, et al. Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clin Cancer Res. 2005;11:7569–7578.
   PubMed Web of Science ®Google Scholar
• Carcaboso AM, Bramuglia GF, Chantada GL, et al. Topotecan vitreous levels after periocular or intravenous delivery in rabbits: An alternative for retinoblastoma chemotherapy. Invest Ophthalmol Vis Sci. 2007;48:3761–3767.
   PubMed Web of Science ®Google Scholar
• Chantada GL, Fandino AC, Carcaboso AM, et al. A phase I study of periocular topotecan in children with intraocular retinoblastoma. Invest Ophthalmol Vis Sci. 2009;50:1492–1496.
   PubMedGoogle Scholar
• Tsao YP, Russo A, Nyamuswa G, et al. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res. 1993;53:5908–5914.
   PubMed Web of Science ®Google Scholar
• Zunino F, Pratesi G. Camptothecins in clinical development. Expert Opin Invest Drugs. 2004;3:269–284.
   Google Scholar
• Wang XZ, Beebe JR, Pwiti L, et al. Aberrant sphingolipid signaling is involved in the resistance of prostate cancer cell lines to chemotherapy. Cancer Res. 1999;59:5842–5848.
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP, Tsavdaridis D, Malamos NA, et al. Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: A phase II study. Cancer Chemother Pharmacol. 2005;56:487–491.
   PubMedGoogle Scholar
• Takahata T, Ookawa K, Suto K, et al. Chemosensitivity determinants of irinotecan hydrochloride in hepatocellular carcinoma cell lines. Basic Clin Pharmacol Toxicol. 2008;102:399–407.
   PubMedGoogle Scholar
• Wang S, Zheng Y, Yu Y, et al. Phosphorylation of beta-actin by protein kinase C-delta in camptothecin analog-induced leukemic cell apoptosis. Acta Pharmacol Sin. 2008;29:135–142.
   PubMedGoogle Scholar
• Hochster H, Kettner E, Kroning H, et al. Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer. Clin Colorectal Cancer. 2005;5:257–262.
   PubMedGoogle Scholar
• Moody TW, Fuselier J, Coy DH, et al. Camptothecin-somatostatin conjugates inhibit the growth of small cell lung cancer cells. Peptides. 2005;26:1560–1566.
   PubMed Web of Science ®Google Scholar
• van Hattum AH, Pinedo HM, Schlüper HM, et al. The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer. Biochem Pharmacol. 2002;64:1267–1277.
   PubMedGoogle Scholar
• Di Felice V, Lauricella M, Giuliano M, et al. The apoptotic effects of cisplatin and carboplatin in retinoblastoma Y79 cells. Int J Oncol. 1998;13:225–232.
   PubMedGoogle Scholar
• Lauricella M, Giuliano M, Emanuele S, et al. Apoptotic effects of different drugs on cultured retinoblastoma Y79 cells. Tumor Biol. 1998;19:356–363.
   PubMedGoogle Scholar
• Suárez F, Jockovich ME, Hernandez E, et al. Paclitaxel in the treatment of retinal tumors of LH beta-Tag murine transgenic model of retinoblastoma. Invest Ophthalmol Vis Sci. 2007;48:3437–3440.
   PubMed Web of Science ®Google Scholar
• Dalgard CL, Van Quill KR, O’Brien JM. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma. Clin Cancer Res. 2008;14:3113–3123.
   PubMed Web of Science ®Google Scholar
• Lee SY, Kim DK, Cho JH, et al. Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma. Arch Ophthalmol. 2008;126:953–958.
   PubMedGoogle Scholar
• Lauricella M, Giuliano M, Emanuele S, et al. Apoptotic effects of different drugs on cultured retinoblastoma Y79 cells. Tumor Biol. 1998;19:356–363.
   PubMedGoogle Scholar
• Zhou Y, Gwadry FG, Reinhold WC, et al. Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: Microarray analysis of dose- and time-dependent effects. Cancer Res. 2002;62:1688–1695.
   PubMed Web of Science ®Google Scholar
• Ullmannova V, Haskovec C. Gene expression during camptothecin-induced apoptosis in human myeloid leukemia cell line ML-2. Neoplasma. 2004;51:175–180.
   PubMedGoogle Scholar
• Chatterjee D, Schmitz I, Krueger A, et al. Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP(short). Cancer Res. 2001;61:7148–7154.
   PubMedGoogle Scholar
• LeBlanc H, Lawrence D, Varfolomeev E, et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med. 2002;8:274–281.
   PubMed Web of Science ®Google Scholar
• McDonald AC, Brown R. Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors. Br J Cancer. 1998;78:745–751.
   PubMedGoogle Scholar
• Vasey PA, Jones NA, Jenkins S, et al. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmakol. 1996;50:1536–1540.
   PubMedGoogle Scholar
• McDermott U, Longley DB, Galligan L, et al. Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer. Cancer Res. 2005;65:8951–8960.
   PubMedGoogle Scholar
• Guo Y, Pajovic S, Gallie BL. Expression of p14ARF, MDM2, and MDM4 in human retinoblastoma. Biochem Biophys Res Commun. 2008;375:1–5.
   PubMedGoogle Scholar
• Pohl BS, Schon C, Rossner A, et al. The FoxO-subclass in Xenopus laevis development. Gene Expr Patterns. 2004;5:187–192.
   PubMedGoogle Scholar
• Arden KC. Multiple roles of FOXO transcription factors in mammalian cells point to multiple roles in cancer. Exp Gerontol. 2006;41:709–717.
   Google Scholar
• Coffer PJ, Burgering BM. Forkhead-box transcription factors and their role in the immune system. Nat Rev Immunol. 2004;4:889–899.
   PubMed Web of Science ®Google Scholar
• Burgring BM, Kops GJ. Cell cycle and death control: Long live Forkheads. Trends Biochem Sci. 2002;27:352–360.
   PubMedGoogle Scholar
• Furukawa-Hibi Y, Kobayashi Y, Chen C, et al. FOXO transcription factors in cell-cycle regulation and the response to oxidative stress. Antioxid Redox Signal. 2005;7:752–760.
   PubMed Web of Science ®Google Scholar
• Lynch RL, Konicek BW, McNulty AM, et al. The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation. Mol Cancer Res. 2005;3:163–169.
   PubMedGoogle Scholar
• Berry E, Hardt JL, Clardy J, et al. Induction of apoptosis in endometrial cancer cells by psammaplysene A involves FOXO1. Gynecol Oncol. 2009;112:331–336.
   PubMedGoogle Scholar
• Li J, Yang L, Song L, et al. Astrocyte elevated gene-1 is a proliferation promoter in breast cancer via suppressing transcriptional factor FOXO1. Oncogene. 2009;28:3188–3196.
   Google Scholar
• Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci. 2007;120:2479–2487.
   PubMed Web of Science ®Google Scholar
• Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell. 1999;96:857–868.
   PubMed Web of Science ®Google Scholar
• Mei Y, Xie C, Xie W, et al. Noxa/Mcl-1 balance regulates susceptibility of cells to camptothecin-induced apoptosis. Neoplasia. 2007;9:871–881.
   Google Scholar
• Liu Y, Xing H, Weng D, et al. Inhibition of Akt signaling by SN-38 induces apoptosis in cervical cancer. Cancer Lett. 2009;274:47–53.
   PubMed Web of Science ®Google Scholar
• Gillings AS, Balmanno K, Wiggins CM, et al. Apoptosis and autophagy: BIM as a mediator of tumor cell death in response to oncogene-targeted therapeutics. FEBS J. 2009;276:6050–6062.
   PubMed Web of Science ®Google Scholar
• Willis SN, Fletcher JI, Kaufmann T, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science. 2007;315:856–859.
   PubMed Web of Science ®Google Scholar
• Kutuk O, Arisan ED, Tezil T, et al. Cisplatin overcomes Bcl-2-mediated resistance to apoptosis via preferential engagement of Bak: Critical role of Noxa-mediated lipid peroxidation. Carcinogenesis. 2009;30:1517–1527
   PubMed Web of Science ®Google Scholar
• Jiang M, Wei Q, Wang J, et al. Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis. Oncogene. 2006;25:4056–4066.
   PubMed Web of Science ®Google Scholar
• Iwase M, Yoshiba S, Uchid M, et al. Enhanced susceptibility to apoptosis of oral squamous cell carcinoma cells subjected to combined treatment with anticancer drugs and phosphatidylinositol 3-kinase inhibitors. Int J Oncol. 2007;31:1141–1147.
   PubMedGoogle Scholar